Endothelial cell surface receptors

Endothelial cell surface receptors represent a broad and heterogeneous category of molecules expressed on the luminal and abluminal surfaces of the vascular endothelium. This group includes critical signaling proteins such as vascular endothelial growth factor receptors (VEGFRs), Tie-2, and endothelin receptors, as well as adhesion molecules like ICAM-1, VCAM-1, and selectins. These receptors are fundamental to vascular homeostasis, regulating processes such as angiogenesis, blood pressure, and the selective recruitment of immune cells from the circulation into tissues. In various diseases, the expression and activity of these receptors are significantly altered. For example, VEGFRs are frequently overexpressed in the tumor microenvironment to facilitate neovascularization, while adhesion molecules are upregulated in chronic inflammatory conditions like multiple sclerosis and Crohn's disease. Consequently, endothelial cell surface receptors are major therapeutic targets. Anti-angiogenic drugs like bevacizumab and ramucirumab are standard of care in oncology and ophthalmology, while therapies targeting endothelial adhesion molecules are used to manage autoimmune and inflammatory disorders. Because these receptors are widely distributed throughout the vasculature, systemic inhibition can lead to characteristic safety concerns such as hypertension and impaired wound healing.

Other names

Endothelial receptorsVascular endothelial receptorsEC surface receptorsVascular surface receptors

Drugs targeting these receptors typically act by inhibiting ligand binding (e.g., blocking VEGF or integrin interactions), inhibiting intracellular kinase activity (e.g., VEGFR tyrosine kinase inhibitors), or modulating receptor-mediated signaling to suppress angiogenesis, reduce vascular permeability, or prevent leukocyte extravasation into tissues.